- Home
- IONS vs GLBE Comparison
IONS vs GLBE Comparison
Compare IONS & GLBE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- GLBE
- Stock Information
- Founded
- IONS 1989
- GLBE 2013
- Country
- IONS United States
- GLBE Israel
- Employees
- IONS N/A
- GLBE N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- GLBE Computer Software: Prepackaged Software
- Sector
- IONS Health Care
- GLBE Technology
- Exchange
- IONS Nasdaq
- GLBE Nasdaq
- Market Cap
- IONS 6.8B
- GLBE 6.0B
- IPO Year
- IONS 1991
- GLBE 2021
- Fundamental
- Price
- IONS $72.93
- GLBE $35.01
- Analyst Decision
- IONS Strong Buy
- GLBE Buy
- Analyst Count
- IONS 21
- GLBE 13
- Target Price
- IONS $80.71
- GLBE $48.77
- AVG Volume (30 Days)
- IONS 2.9M
- GLBE 1.2M
- Earning Date
- IONS 10-29-2025
- GLBE 11-19-2025
- Dividend Yield
- IONS N/A
- GLBE N/A
- EPS Growth
- IONS N/A
- GLBE N/A
- EPS
- IONS N/A
- GLBE N/A
- Revenue
- IONS $966,957,000.00
- GLBE $843,642,000.00
- Revenue This Year
- IONS $27.96
- GLBE $28.17
- Revenue Next Year
- IONS $2.33
- GLBE $24.07
- P/E Ratio
- IONS N/A
- GLBE N/A
- Revenue Growth
- IONS 20.41
- GLBE 33.30
- 52 Week Low
- IONS $23.95
- GLBE $26.64
- 52 Week High
- IONS $76.78
- GLBE $63.69
- Technical
- Relative Strength Index (RSI)
- IONS 55.70
- GLBE 46.46
- Support Level
- IONS $68.22
- GLBE $34.24
- Resistance Level
- IONS $74.50
- GLBE $37.29
- Average True Range (ATR)
- IONS 3.36
- GLBE 1.18
- MACD
- IONS -0.55
- GLBE -0.09
- Stochastic Oscillator
- IONS 64.72
- GLBE 28.31
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About GLBE Global-E Online Ltd.
Global E Online Ltd provides e-commerce solutions. The company offers a platform to enable and accelerate direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from and anywhere in the world. The company localizes the shopper experience to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce. The company derives maximum revenue from the United States.